Oregon Department of Corrections
Approved Formulary
Search by name
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Add Formweb to your mobile device
Android
iOS
Home
QuickStart
Admin
February P&T meeting minutes have been posted.
Oregon Department of Corrections
Approved Formulary
Search by name
Additional search options
Search by class
Browse alphabetically
Select...
NUM
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Hazardous Drugs
In-Cell HD
Earned In-Cell
Formulary Duration Restrictions
Therapeutic Substitutions
Webpage Links
Search results for:
ziprasidone
ziprasidone
Hazardous Drugs
Handling Guide (Group 3: Reproductive Risk)
Cell Status
NFISA
Brand names:
Geodon, Ziprasidone HYDROCHLORIDE
Form
Strength
CAPSULE, ORAL
20 mg; 40 mg; 60 mg; 80 mg
POWDER FOR INJECTION, INTRAMUSCULAR
20 mg
Additional Information:
JANUARY 2021 P&T MINUTES
FEBRUARY 2020 P&T MINUTES
JUNE 2011 P&T MINUTES
Last updated:
Dec. 19, 2022
Black Box Warning:
Mortality in elderly with dementia related psychosis
FDA Drug Safety:
Antipsychotic drug labels updated on use during pregnancy and risk of abnormal muscle movements and withdrawal symptoms in newborns
FDA Drug Safety:
Mental health drug ziprasidone (Geodon) associated with rare but potentially fatal skin reactions
UpToDate
Micromedex
Pharmacist's Letter
FDA DailyMed Package Insert
WebMD Pill Identifier
JANUARY 2021 P&T MINUTES
FEBRUARY 2020 P&T MINUTES
JUNE 2011 P&T MINUTES